AstraZeneca Annual Report and Operational Review Form 20-F Information 2004 15 Gastrointestinal GI We aim to maintain our Products In March 2004, Dr Reddys Laboratories Nexium esomeprazole magnesium is Ltd. opened a Drug Master File with the number one position in the first proton pump inhibitor PPI to offer FDA relating to the active ingredient of GI treatments through clinical improvements over other PPIs Nexium, esomeprazole magnesium.
such as Losec Prilosec, lansoprazole However, AstraZeneca is not aware of continued market and pantoprazole and other treatments.
the filing of an Abbreviated New Drug penetration for Nexium Nexium has been evaluated in clinical Application relating to esomeprazole studies involving 73,000 patients in over magnesium.
It offers more effective acid high quality innovation and inhibition than all other PPIs and, in the Losec Prilosec omeprazole, the first treatment of reflux oesophagitis, provides PPI, became established in the short productivity in the research healing and symptom relief in more and long term treatment of acid-related and development of new patients and in a shorter period of time diseases in the 1980s and 1990s.
Patients than Losec Prilosec, lansoprazole or have benefited from over 780 million GI therapies.
It is an effective, long term treatments with Losec Prilosec since therapy for patients with GERD, with or launch.
Continued strong sales growth of without oesophagitis.
For the treatment Losec Omepral was seen in Japan in 2004. of active peptic ulcer disease, seven day Therapy area overview Nexium triple therapy in combination Patent protection for omeprazole, the active World PPI market value: with two antibiotics for the eradication of ingredient in Losec Prilosec, has expired.
H. pylori heals most patients without the a small number of countries, including some need for follow up anti-secretory therapy.
major markets, patent term extensions or In the western world, 40% of adults supplementary protection certificates have regularly experience heartburn and Nexium is used to treat a wide range been granted for the active ingredient.
10-20% have gastro-oesophageal reflux of patients with acid-related disorders, Further information about the status of disease GERD.
The prevalence rate including both newly diagnosed and also omeprazole patents and patent litigation, of GERD in Asia is lower but increasing.
patients switched from other therapies including details of generic omeprazole such as omeprazole, other PPIs and launches, is set out on pages 112 and 113.
Helicobacter pylori H. pylori is the major H2-receptor antagonists.
cause of peptic ulcer disease and In July 2003, the European Commission is a risk factor for gastric cancer.
The Nexium was first launched in Sweden served a Statement of Objections on prevalence rate of H. pylori infection in in August 2000 and it is now available AstraZeneca, referring to alleged the western world is 40% but declining.
in approximately 100 markets, including infringements of European competition law the US, Canada and all European countries.
relating to certain omeprazole intellectual Irritable bowel syndrome IBS is a It has been well received by patients and property and regulatory rights, details of common gastrointestinal disease which physicians alike and close to 250 million which are set out on page 113. is inadequately treated.
The prevalence patient treatments had been administered rate in the population is 20%.
Entocort budesonide is a locally acting corticosteroid for the treatment of IBD with Inflammatory bowel disease IBD is an First regulatory approval and launch of better tolerability than other corticosteroids area of significant unmet medical need.
parenteral Nexium were achieved in 2003. and greater efficacy than aminosalicylic acid The parenteral form of Nexium was approved medicines.
Entocort maintained its growth 2004 in brief through the Mutual Recognition Procedure during 2004, based on its increasing MRP in Europe in December 2003 for when acceptance as first line therapy for mild to Global sales of Nexium were oral administration is not applicable for the moderate, active Crohns disease.
Subsequent approvals Entocort was approved for paediatric use have been obtained during 2004 and in nine countries, representing the first such Nexium confirmed as the most parenteral Nexium is now approved in 47 use for a Crohns disease therapy successful US pharmaceuticals countries.
Regulatory filings of Nexium for worldwide.
launch with in excess of $3.5 billion healing and prevention of ulcers, associated sales in 30 months.
with NSAID non-steroidal anti-inflammatory Pipeline drug therapy were made in January 2004.
In addition to exploring new areas of clinical Nexium parenteral is approved in The application was approved through the use for Nexium and further strengthening 47 countries and approval of Nexium MRP in Europe in September 2004 and the scope of its use in current areas, we for healing and prevention of ulcers subsequent, national approvals have been focus on developing novel approaches to associated with NSAID therapy has been obtained in 11 EU countries to date.
treating GERD, peptic ulcer disease, IBD granted in the first 11 EU countries.
Approval for the reduction in the occurrence and other gastrointestinal diseases, such of gastric ulcers associated with continuous as IBS and functional dyspepsia.
Global sales of Losec $1,947 million NSAID therapy in patients at risk of with continued strong sales growth developing gastric ulcers was granted in AZD0865 is a compound in a new class, in Japan.
the US in November 2004.  acid blockers AstraZeneca Annual Report and Operational Review 16 Form 20-F Information 2004 Sales growth is shown in both reported and underlying performance.
Reported performance takes into account all the factors including those which we cannot influence, principally currency exchange rates that have affected the results of our business.
Underlying performance shows sales growth at constant exchange rates CER to reflect the volume and price changes of the geographic and therapy areas and individual products by excluding the effects of exchange.
A description of the calculation of this measure is set out in the Financial Review on page 38, together with the reasons for its use.
Key product performance 2004 2003 2002 2004 compared to 2003 2003 compared to 2002 Growth Growth due to due to Growth exchange Growth exchange Growth Growth Growth Growth Sales underlying effects Sales underlying effects Sales underlying reported underlying reported $m $m $m $m $m $m $m %% %% Nexium 3,883 479 102 3,302 1,225 99 1,978 15 18 62 67 Losec Prilosec 1,947 764 146 2,565 2,259 201 4,623 30 24 49 45 Other 88 7 576 8 563 916 13 21 Total 5,918 278 253 5,943 1,026 305 6,664 4 16 11 P-CABs, that has potential to provide volume growth was also the driver behind the US was 27.4% as four more generic faster, more effective and reliable inhibition the 41% increase in the rest of the world.
versions of omeprazole entered the market of gastric acid secretion than PPIs in the and Proctor & Gamble launched the first treatment of acid-related diseases, such US sales for Prilosec for the full year at over-the-counter OTC version of the as GERD.
$366 million were down 58% in line with brand, Losec Prilosec OTC.
Outside the the decline in prescriptions.
US, sales fell by 16%, although there AZD3355 and AZD9343, now in clinical was strong growth in Japan where sales development, are reflux inhibitors offering Outside the US, sales of Losec were increased by 39% from $92 million to a potential breakthrough in the treatment $1,581 million, down 16% for the year.
of GERD through a new, targeted approach Full year sales increased 24% in Japan other than inhibition of acid secretion, to $185 million.
Sales in Europe declined namely inhibition of transient relaxations by 25%, principally through volume, of the lower oesophageal sphincter.
AZD7371 is being evaluated in clinical Performance 2003 studies for the treatment of functional GI Reported performance diseases and is in phase 2.
Reported sales in the GI therapy area fell by 11% to $5,943 million as increases in AZD8081, for the treatment of functional Nexium sales were offset by declines in GI diseases, and AZD5745, for the Losec Prilosec sales.
treatment of acid-related diseases, are both in pre-clinical development.
Underlying performance Exchange effects on sales in 2003 Performance 2004 amounted to $305 million.
As a Reported performance consequence, the underlying sales decline GI performance in 2004 was broadly the at 16%, was higher than reported.
same as 2003, with sales falling by only $25 million.
Global sales performance for Nexium was strong, particularly in the US where total Underlying performance prescriptions for Nexium overtook those On an underlying basis, GI sales fell by 4% for Losec Prilosec during the year.
$278 million as declines in Losec Prilosec Sales of Nexium in the US for the full year exceeded growth in Nexium.
Total prescriptions for Nexium were up 46% and In the US, dispensed tablet volume for its share of total prescriptions in the US PPI Nexium increased by 20% for the year.
As market grew by nearly five percentage the impact of price was broadly neutral, points over the course of the year, to 25.3%.
reported sales growth of 10% up to $2,716 million reflects stock movements.
Sales of Nexium outside the US increased Nexium share of total prescriptions in the by 60% for the full year, with excellent US PPI market was 27.1% in December growth in the major markets in Europe, 2004.
The increase of 1.8 points in market particularly France, Germany and the UK, share versus 2003 outpaced all other PPI and a strong performance in Australia.
Sales of Nexium outside the US were $1,167 million for the full year, up 29% Losec Prilosec sales were down by 49% on a strong performance in all major for the year.
The 70% decline in the US was markets.
Sales in Europe reached $873 broadly in line with the prescription trend.
million up 26% as volume growth was At the end of the year Losec Prilosec brand offset in part by pricing pressures.
Strong share of total omeprazole prescriptions in
